FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase

por Flamme, Ingo, Ellinghaus, Peter, Urrego, Diana, Krüger, Thilo
Publicado 2017

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?

por Ellinghaus, Peter, Neureiter, Daniel, Nogai, Hendrik, Stintzing, Sebastian, Ocker, Matthias
Publicado 2022

Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects

por Flamme, Ingo, Oehme, Felix, Ellinghaus, Peter, Jeske, Mario, Keldenich, Jörg, Thuss, Uwe
Publicado 2014

Deguelin Attenuates Reperfusion Injury and Improves Outcome after Orthotopic Lung Transplantation in the Rat

por Paulus, Patrick, Ockelmann, Pia, Tacke, Sabine, Karnowski, Nora, Ellinghaus, Peter, Scheller, Bertram, Holfeld, Johannes, Urbschat, Anja, Zacharowski, Kai
Publicado 2012

Elevated plasma levels of TNF-alpha and Interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders

por Dinh, Wilfried, Füth, Reiner, Nickl, Werner, Krahn, Thomas, Ellinghaus, Peter, Scheffold, Thomas, Bansemir, Lars, Bufe, Alexander, Barroso, Michael Coll, Lankisch, Mark
Publicado 2009

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

por Schmieder, Roberta, Hoffmann, Jens, Becker, Michael, Bhargava, Ajay, Müller, Tina, Kahmann, Nicole, Ellinghaus, Peter, Adams, Robert, Rosenthal, André, Thierauch, Karl-Heinz, Scholz, Arne, Wilhelm, Scott M, Zopf, Dieter
Publicado 2014

BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I

por Ellinghaus, Peter, Heisler, Iring, Unterschemmann, Kerstin, Haerter, Michael, Beck, Hartmut, Greschat, Susanne, Ehrmann, Alexander, Summer, Holger, Flamme, Ingo, Oehme, Felix, Thierauch, Karlheinz, Michels, Martin, Hess-Stumpp, Holger, Ziegelbauer, Karl
Publicado 2013

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

por Grünewald, Sylvia, Politz, Oliver, Bender, Sebastian, Héroult, Mélanie, Lustig, Klemens, Thuss, Uwe, Kneip, Christoph, Kopitz, Charlotte, Zopf, Dieter, Collin, Marie‐Pierre, Boemer, Ulf, Ince, Stuart, Ellinghaus, Peter, Mumberg, Dominik, Hess‐Stumpp, Holger, Ziegelbauer, Karl
Publicado 2019

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

por Sternberg, Cora N., Petrylak, Daniel P., Bellmunt, Joaquim, Nishiyama, Hiroyuki, Necchi, Andrea, Gurney, Howard, Lee, Jae-Lyun, van der Heijden, Michiel S., Rosenbaum, Eli, Penel, Nicolas, Pang, See-Tong, Li, Jian-Ri, García del Muro, Xavier, Joly, Florence, Pápai, Zsuzsanna, Bao, Weichao, Ellinghaus, Peter, Lu, Chengxing, Sierecki, Mitchell, Coppieters, Sabine, Nakajima, Keiko, Ishida, Tatiane Cristine, Quinn, David I.
Publicado 2023